Exactech, Inc. (EXAC) updated its FY12 earnings guidance on Tuesday. The company provided EPS guidance of $0.93-0.95 for the period. Exactech also updated its Q4 guidance to $0.26-$0.28 EPS.

On a related note, analysts at Benchmark Co. reiterated a buy rating on shares of Exactech in a research note to investors on Friday, September 14th. They now have a $21.00 price target on the stock.

Shares of Exactech, Inc. (EXAC) remained flat at $16.12 during during mid-day trading trading on Tuesday. Exactech, Inc. (EXAC) has a 52 week low of $13.58 and a 52 week high of $18.50. The company has a market cap of $213.9 million and a P/E ratio of 22.45.

Exactech last announced its earnings results on Tuesday, October 30th. The company reported $0.19 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.17 by $0.02. The company had revenue of $51.30 million for the quarter, compared to the consensus estimate of $50.20 million. The company’s revenue for the quarter was up 8.5% on a year-over-year basis. Analysts expect that Exactech, Inc. (EXAC) will post $0.92 EPS for the current fiscal year.

Exactech, Inc. (Exactech) develops, manufactures, markets and distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians in the United States and internationally.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.